Imagen de Portada

Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Polly Paul, Pieter J. Colin, Flora Musuamba Tshinanu, Carolien Versantvoort, Efthymios Manolis, Kevin Blake
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA
por: Polly Paul, et al.
Publicado: (2025)

Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?
por: Nisha Sharma, et al.
Publicado: (2024)

Why Pediatric CAR ‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe
por: Lisa Hanquet, et al.
Publicado: (2026)

Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing
por: Ian T.T. Liu, et al.
Publicado: (2026)

Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future
por: Karen Rowland Yeo, et al.
Publicado: (2024)

Japan's Conditional/Time‐Limited Early Approval System in Regenerative Medicine: A Case Study of Rise and Falls of Autologous Skeletal Myoblast Sheets
por: Hayase Hakariya, et al.
Publicado: (2025)

Use of FDA Expedited Programs and Development Timelines for New Molecular Entity Drug and New Biologic Approvals by Sponsor Experience
por: Kanhai S. Amin, et al.
Publicado: (2025)

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations
por: Jorge Madrid Paredes, et al.
Publicado: (2024)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
por: Jeffrey D McCurdy, et al.
Publicado: (2025)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
por: Janne T. Backman
Publicado: (2025)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
por: Kunal S. Taskar, et al.
Publicado: (2025)

How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study
por: Olha Shuklinova, et al.
Publicado: (2024)

Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
por: Md Masud Parvez, et al.
Publicado: (2024)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight
por: Jae Hyeon Yu, et al.
Publicado: (2024)

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form
por: Vivek Purohit, et al.
Publicado: (2024)

Is a Clinical Trial With a Non‐Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK
por: Jin Dong, et al.
Publicado: (2026)

Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling
por: Friederike Kanefendt, et al.
Publicado: (2024)

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results
por: Michael Camilleri, et al.
Publicado: (2026)

Assessment of Efficacy Evidence for Approvals of Novel Drugs in China Between 2018 and 2022
por: Yang Xu, et al.
Publicado: (2024)

Expedited Approval in Oncology: A Study of European Regulators' Perspectives and Trade‐Offs
por: Francesco Pignatti, et al.
Publicado: (2025)

Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
por: Yow‐Ming C. Wang, et al.
Publicado: (2024)

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
por: Mohamed A. Kamal, et al.
Publicado: (2024)

Reply to the Commentary: Should Injectable Meloxicam Be Approved for Use in Cats?
por: Ludovic Pelligand, et al.
Publicado: (2026)

Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection—Authors' Reply
por: Milou. L. M. van Riswijk, et al.
Publicado: (2025)

Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
por: Ting Wang, et al.
Publicado: (2025)

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
por: Sachiko Mita, et al.
Publicado: (2025)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
por: Kenichi Umehara, et al.
Publicado: (2024)

FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose
por: Srikanth C. Nallani, et al.
Publicado: (2024)

Characteristics of Drugs from Non‐Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval
por: Kensuke Matsuda, et al.
Publicado: (2024)

Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan
por: Kensuke Matsuda, et al.
Publicado: (2025)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
por: Xingfei Pan, et al.
Publicado: (2025)

B‐ and T‐Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis
por: Andrew C. Vendel, et al.
Publicado: (2024)

Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
por: Gabriel K. Innes, et al.
Publicado: (2025)

Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain
por: Qianxi Lou, et al.
Publicado: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis
por: Thomas Dumortier, et al.
Publicado: (2025)

Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
por: Jie Zhang, et al.
Publicado: (2025)

Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
por: Minji Kim, et al.
Publicado: (2026)

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data
por: Gaurav Bajaj, et al.
Publicado: (2025)